Business context and reporting period
The supplied filing is Amarillo Biosciences, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2012—not a filing identified as Ainos, Inc. Investors should verify the issuer and filing before relying on this summary. Amarillo was developing low-dose oral interferon for human and animal uses; reported revenue was negligible.
Financial results and liquidity
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $50 | $50,480 | $530 | $58,035 |
| Gross margin | $30 | $50,288 | $318 | $53,824 |
| Operating expenses | $131,635 | $514,558 | $435,362 | $1,006,507 |
| Operating loss | $(131,605) | $(464,270) | $(435,044) | $(952,683) |
| Net loss | $(146,775) | $(534,807) | $(511,516) | $(1,083,363) |
At September 30, 2012, cash was $302, current assets were $15,160, current liabilities were $4,225,876, and working capital deficit was $4,210,716. Total liabilities were $4,225,876; stockholders’ deficit was $4,112,718. Related-party notes payable were $2,635,584, with accrued interest to related parties of $926,753. The company reported a roughly $55,000 monthly cash burn rate. Nine-month operating cash use was $384,027, partly offset by $385,584 of financing cash flow; ending cash was $302. No meaningful operating margin is evident given the minimal revenue and operating losses.
Changes versus prior comparable periods
Revenue fell sharply: Q3 revenue declined about 99.9%, mainly because the prior-year quarter included a $50,000 sublicense fee; nine-month revenue declined about 99.1%, with no 2012 sublicense fee and lower product sales. Operating expenses and losses fell substantially, largely from lower selling, general and administrative costs, including reduced professional, legal, personnel, and public/investor relations expenses. Net losses also narrowed, aided by a derivative fair-value gain of $15,096 in Q3 and $37,750 for the nine-month period, versus losses in 2011. These noncash derivative gains and expense reductions did not resolve the company’s liquidity shortfall.
Outlook, risks, contingencies, and unusual items
- Management stated that continued losses and lack of liquidity raised substantial doubt about the company’s ability to continue as a going concern. It was pursuing investors and pharmaceutical partners; there was no assurance that funding would be secured. Potential equity financing could materially dilute shareholders or change control.
- After quarter-end, the company reported that Hayashibara had notified it of termination of the supply agreement, effective December 22, 2012, and had halted interferon production. Amarillo said it would likely terminate agreements with Bumimedic, CytoPharm, Intas, and Cadila because it could no longer supply Hayashibara interferon. Cadila’s agreement had already terminated effective August 17, 2012.
- The company was in repayment default on two $1 million HBL notes, although HBL had not demanded repayment. Demand could worsen the company’s cash position. It also had a $200,000 director note and related-party working-capital advances; additional $54,693 in CEO advances was received from October 1 through November 7, 2012.
- Research and product commercialization remained dependent on further development, clinical testing, regulatory approval, third-party manufacturing and distribution, and financing. Management reported preliminary hepatitis C study results: the primary endpoint was not achieved, although selected subgroup and platelet-normalization observations were described; follow-up studies were being planned.
- Unusual financing and equity items included $445,584 in related-party note proceeds, preferred stock issued for debt, interest and dividends, and $278,259 of accrued salary and benefits forgiven. The filing reported disclosure controls effective and no significant internal-control changes; no legal proceedings were reported.
Important facts to verify
- Confirm the issuer: the filing text names Amarillo Biosciences, Inc., not Ainos, Inc.
- Verify current cash, funding availability, monthly burn, and ability to meet near-term obligations given the $4.21 million working-capital deficit.
- Confirm the status and repayment terms of HBL debt, the supply-agreement termination, and any resulting licensee contract terminations.
- Review the potential dilution from outstanding warrants, options, preferred-stock conversions, and future financing; the filing reported 13,236,109 shares reserved for issuance.
- Assess the clinical evidence and regulatory path for oral interferon, including the hepatitis C study’s unmet primary endpoint and planned follow-up work.